TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37717638

Group type: EXPERIMENTAL
Intervention: SHHC-2.0 intervention (24 weeks of twice-weekly experiential nutrition education and group-based physical activity classes)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: SHHC-2.0 intervention
Number of subjects: 182
Study: 37717697

Group type: EXPERIMENTAL
Intervention: Early ultrasound scan (31 weeks gestational age ±6 days)
Number of subjects: 3701

Group type: COMPARATOR
Intervention: Late ultrasound scan (35 weeks gestational age ±6 days)
Number of subjects: 3701
Study: 37717786

Group type: EXPERIMENTAL
Intervention: Hypofractionated proton beam radiation therapy (PBT) at dose level 1 (DL1) - 5 Gy × 5 fractions, administered on days 15 to 19 in a 28-day cycle before starting cycle 7 of mFFX.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypofractionated proton beam radiation therapy (PBT) at dose level 2 (DL2) - 5 Gy × 5 fractions, administered on days 8 to 12 in a 21-day cycle before starting cycle 7 of mFFX.
Number of subjects: 9
Study: 37717787

Group type: EXPERIMENTAL
Intervention: Single-Fraction Stereotactic Radiosurgery (SF-SRS)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Multifraction Stereotactic Radiosurgery (MF-SRS)
Number of subjects: 404
Study: 37717851

Group type: EXPERIMENTAL
Intervention: Provider opinion baseline
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Provider opinion univariable logistic regression
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Random forest classifier
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Extreme gradient boosting
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Artificial neural network
Number of subjects: 984
Study: 37717908

Group type: EXPERIMENTAL
Intervention: Parent-driven language intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Health-safety lessons (control)
Number of subjects: 95
Study: 37717936

Group type: EXPERIMENTAL
Intervention: Anticoagulation plus supplemental oxygen for the first 48 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ambient air (control)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Anticoagulation plus supplemental oxygen
Number of subjects: 70
Study: 37718234

Group type: EXPERIMENTAL
Intervention: Technetium-99m-mercaptoacetyltriglycine diuretic renography at timepoint 1
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Standard parameters for differential renal function development
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Tissue tracer transit
Number of subjects: 37
Study: 37718392

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 931
Study: 37718442

Group type: EXPERIMENTAL
Intervention: DeCIDE PC intervention
Number of subjects: 0
Study: 37718446

Group type: EXPERIMENTAL
Intervention: LPB at L3 level (P group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: T12 paravertebral block combined with LPB at L3 and L4 levels (TP group)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: LPB combined with TQLB at L3 level (PQ group)
Number of subjects: 84
Study: 37718441

Group type: EXPERIMENTAL
Intervention: 4D flow CMR analysis
Number of subjects: 163
Study: 37718471

Group type: EXPERIMENTAL
Intervention: Budesonide Oral Suspension (BOS) 2.0 mg twice daily (b.i.d.)
Number of subjects: 76
Study: 37718721

Group type: EXPERIMENTAL
Intervention: Pegozafermin 27 mg once weekly for 20 weeks
Number of subjects: 20
Study: 37718930

Group type: EXPERIMENTAL
Intervention: Mini-dose Bier's block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 0
Study: 37718932

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348

Group type: EXPERIMENTAL
Intervention: All treatments (FIL200, FIL100, placebo)
Number of subjects: 1348
Study: 37719091

Group type: EXPERIMENTAL
Intervention: Increased physical activity (500 steps/day weekly until 10,000 steps/day)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Active participants
Number of subjects: 379

Group type: COMPARATOR
Intervention: Less active participants
Number of subjects: 379
Study: 37719417

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination (1 intradermal dose of 0.1 mL)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination
Number of subjects: 84
Study: 37719467

Group type: EXPERIMENTAL
Intervention: Remotely delivered Spring Forest Qigong
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37719735

Group type: EXPERIMENTAL
Intervention: GDP per capita
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Access to electricity
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Political stability, absence of violence/terrorism
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Civil liberties
Number of subjects: 205
Study: 37720011

Group type: EXPERIMENTAL
Intervention: Assisted index case testing
Number of subjects: 26
Study: 37720013

Group type: EXPERIMENTAL
Intervention: BRIGHT (5 weekly psychologist-led video tele-CBT sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attention Control (dose-and delivery matched survivorship education)
Number of subjects: 44
Study: 37720025

Group type: EXPERIMENTAL
Intervention: OEND intervention (naloxone distribution and overdose education)
Number of subjects: 29
Study: 37720027

Group type: EXPERIMENTAL
Intervention: PEGPH20
Number of subjects: 29
Study: 37720040

Group type: EXPERIMENTAL
Intervention: Laboratory-based PCR viral testing
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) antigen testing
Number of subjects: 69

Group type: COMPARATOR
Intervention: Laboratory-based PCR viral testing and POC testing
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Testing protocols for DHCWs and patients
Number of subjects: 69
Study: 37720052

Group type: EXPERIMENTAL
Intervention: FIRST (transdiagnostic intervention built on five empirically supported principles of change)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 212
Study: 37720184

Group type: EXPERIMENTAL
Intervention: Management of new-onset LBBB post-TAVI
Number of subjects: 0
Study: 37720185

Group type: EXPERIMENTAL
Intervention: Participation in ICU rounds (N = 16)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual-care group (N = 11)
Number of subjects: 27
Study: 37720373

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic (MSP) supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 37720456

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - eight sessions of group-based CBT (every 2-3 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (usual oncology care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 37720495

Group type: EXPERIMENTAL
Intervention: Low neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Pan-immune-inflammation value (PIV)
Number of subjects: 1274
Study: 37720540

Group type: EXPERIMENTAL
Intervention: Sensor Augmented Pump (SAP) therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Multiple Daily Injection (MDI) therapy
Number of subjects: 46
Study: 37720564

Group type: EXPERIMENTAL
Intervention: Omadacycline treatment at 16× the MIC for 72 hours
Number of subjects: 0
Study: 37720591

Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr) delivered via smartphone app for four weeks, including mindfulness and cognitive behavioral therapy modules.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile app-based self-guided psychological intervention (Nałogometr).
Number of subjects: 0
Study: 37720695

Group type: EXPERIMENTAL
Intervention: Early 75 g OGTT at 12-15 weeks of gestation
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: Lowering postload glucose values (75 g OGTT cut-off values of 5.1, 8.9, and 7.8 mmol/L)
Number of subjects: 829
Study: 37720924

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 1604

Group type: COMPARATOR
Intervention: Microsurgery (MS)
Number of subjects: 1604
Study: 37720929

Group type: EXPERIMENTAL
Intervention: Natural orifice specimen extraction colectomy (NC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional laparoscopic colorectal resection (CLR)
Number of subjects: 99
Study: 37721127

Group type: EXPERIMENTAL
Intervention: MAP65 group (target MAP 65 mmHg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: APP60 group (target APP > 60 mmHg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MAP65 group
Number of subjects: 72

Group type: COMPARATOR
Intervention: APP60 group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 37721470

Group type: EXPERIMENTAL
Intervention: Adjunctive COX-2 inhibitor etoricoxib
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 15
Study: 37721581

Group type: EXPERIMENTAL
Intervention: novel somatostatin receptor (SSTR) antagonist
Number of subjects: 15

Group type: COMPARATOR
Intervention: not available
Number of subjects: 15
Study: 37721703

Group type: EXPERIMENTAL
Intervention: Uncomplicated phacoemulsification with IOL implantation in diabetic patients with PEX (Group 1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Uncomplicated phacoemulsification with IOL implantation in diabetic patients (Group 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Uncomplicated phacoemulsification with IOL implantation in patients with PEX (Group 3)
Number of subjects: 61
Study: 37721735

Group type: EXPERIMENTAL
Intervention: 2 hours of after-school physical activity time outdoors on school days
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Free arrangement of after-school activity (control group)
Number of subjects: 2032
Study: 37721734

Group type: EXPERIMENTAL
Intervention: Telehealth dementia care program with an unlicensed dementia care guide providing caregiver support and education.
Number of subjects: 460
Study: 37721738

Group type: EXPERIMENTAL
Intervention: AI-enabled automated LVO detection from CT angiogram with secure messaging
Number of subjects: 243
Study: 37721754

Group type: EXPERIMENTAL
Intervention: Cetuximab maintenance therapy after FOLFIRI plus cetuximab induction therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Observation after FOLFIRI plus cetuximab induction therapy
Number of subjects: 139
Study: 37721786

Group type: EXPERIMENTAL
Intervention: 12-week tele-RHB program along with CPAP therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: CPAP therapy alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: tele-RHB program and CPAP therapy
Number of subjects: 50
Study: 37721790

Group type: EXPERIMENTAL
Intervention: Social VR training
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional social skills training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Social VR training and Traditional social skills training
Number of subjects: 90
Study: 37721791

Group type: EXPERIMENTAL
Intervention: AT-Patch device
Number of subjects: 320
Study: 37721795

Group type: EXPERIMENTAL
Intervention: Bright Light (BL) therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dim Light (DL) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 60
Study: 37721952

Group type: COMPARATOR
Intervention: Warning labels
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Tax (30% price increase)
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Combined warning labels + tax
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Combined condition
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Tax condition
Number of subjects: 3518
Study: 37721964

Group type: EXPERIMENTAL
Intervention: Ivermectin + Albendazole (IA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Moxidectin + Albendazole (MoxA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ivermectin + Diethylcarbamazine + Albendazole (IDA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Moxidectin + Diethylcarbamazine + Albendazole (MoxDA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Triple drug treatments (IDA, MoxDA)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Baseline Mf counts
Number of subjects: 164
Study: 37721990

Group type: COMPARATOR
Intervention: Oral Δ
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37722087

Group type: EXPERIMENTAL
Intervention: abemaciclib
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: neratinib
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: CC-115
Number of subjects: 237

Group type: COMPARATOR
Intervention: control
Number of subjects: 237
Study: 37722131

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37722196

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Women with diabetes
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Women with hyperlipidemia
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Women with hypertension
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Age stratification
Number of subjects: 382
Study: 37722238

Group type: EXPERIMENTAL
Intervention: Neurofeedback intervention (2 sessions)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Yoked sham feedback (control group)
Number of subjects: 36
Study: 37722357

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy followed by autologous stem cell transplantation
Number of subjects: 113
Study: 37722354

Group type: EXPERIMENTAL
Intervention: ibrutinib + CIT (560 mg daily plus 6 cycles of BR/R-CHOP)
Number of subjects: 403

Group type: COMPARATOR
Intervention: placebo + CIT (placebo daily plus 6 cycles of BR/R-CHOP)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: ibrutinib + CIT
Number of subjects: 403

Group type: COMPARATOR
Intervention: placebo + CIT
Number of subjects: 403
Study: 37722483

Group type: EXPERIMENTAL
Intervention: PolarX cryoballoon ablation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Arctic Front cryoballoon ablation
Number of subjects: 200
Study: 37722482

Group type: EXPERIMENTAL
Intervention: Team-based home blood pressure monitoring (HBPM) with a clinical pharmacist, including pro-active outreach, provision of BP devices, automated texting, visit note template, audit and feedback, and training.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team-based home blood pressure monitoring (HBPM) with a clinical pharmacist.
Number of subjects: 0
Study: 37722559

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard conditions
Number of subjects: 50
Study: 37722662

Group type: EXPERIMENTAL
Intervention: Integrated malaria-helminth treatment approach
Number of subjects: 57
Study: 37722831

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Number of subjects: 118
Study: 37723109

Group type: EXPERIMENTAL
Intervention: Buffered long-acting local anaesthetic (lidocaine and bupivacaine with epinephrine)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-buffered long-acting local anaesthetic (lidocaine and bupivacaine with epinephrine)
Number of subjects: 116
Study: 37723108

Group type: EXPERIMENTAL
Intervention: Remotely administered adherence programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37723113

Group type: EXPERIMENTAL
Intervention: GAMAD diagnostic model based on gender, age, multitarget circulating tumour DNA methylation signature and serological biomarkers (AFP, DCP)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard imaging techniques and serum markers (not specified)
Number of subjects: 2000
Study: 37723115

Group type: EXPERIMENTAL
Intervention: Plasma sCLEC-2 levels measured at first visit and 7 days later or at discharge in patients with AIS/TIA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: sCLEC-2/D-dimer ratio
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Correlation of sCLEC-2
Number of subjects: 600
Study: 37723198

Group type: EXPERIMENTAL
Intervention: Patient-derived-xenograft (PDX) models established in immunocompromised mice
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Histology, whole exome and RNA sequencing
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Molecular characterization of patients
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Sharing of 90 models with IMI2 ITCC Pediatric Preclinical Proof-of-concept Platform
Number of subjects: 131
Study: 37723272

Group type: EXPERIMENTAL
Intervention: 10-week parent support program with follow-up booster sessions (PGB)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 10-week parent support program without follow-up booster sessions (PGNB)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard outpatient treatment (ST)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: %IOTF25 for PGB
Number of subjects: 171

Group type: COMPARATOR
Intervention: %IOTF25 for ST
Number of subjects: 171
Study: 37723356

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37723430

Group type: EXPERIMENTAL
Intervention: Midwife-provided orientation of birth companions
Number of subjects: 475

Group type: COMPARATOR
Intervention: Control group (no midwife-provided orientation)
Number of subjects: 475
Study: 37723439

Group type: EXPERIMENTAL
Intervention: GALAD score and semi-annual abdominal ultrasound for five years
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced MRI annually for five years
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Bootstrap resampling technique and Cox proportional hazards regression model
Number of subjects: 1600
Study: 37723467

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard prophylactic medication
Number of subjects: 220
Study: 37723498

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation strategies (specific details not provided)
Number of subjects: 2479
Study: 37723516

Group type: EXPERIMENTAL
Intervention: Video-thoracoscopy
Number of subjects: 259

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 259
Study: 37723577

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg QD
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo to Upadacitinib
Number of subjects: 420
Study: 37723590

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cabozantinib and nivolumab
Number of subjects: 15
Study: 37723837

Group type: EXPERIMENTAL
Intervention: Sintilimab plus anlotinib
Number of subjects: 21
Study: 37724431

Group type: EXPERIMENTAL
Intervention: Salivette® Cortisol (SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oropharyngeal swabbing
Number of subjects: 0
Study: 37724527

Group type: EXPERIMENTAL
Intervention: Probiotics for 7 consecutive days
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo for 7 consecutive days
Number of subjects: 92
Study: 37724785

Group type: EXPERIMENTAL
Intervention: Low-intensity resistance training with blood flow restriction (LIRT-BFR)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-intensity resistance training (HIRT)
Number of subjects: 32
Study: 37725026

Group type: EXPERIMENTAL
Intervention: Focal boost with D98% of 95 Gy
Number of subjects: 526

Group type: COMPARATOR
Intervention: Standard whole-gland radiation therapy of 77 Gy
Number of subjects: 526
Study: 37725082

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 37725234

Group type: EXPERIMENTAL
Intervention: 2.9 mm diameter bone-level-tapered implant
Number of subjects: 41
Study: 37725409

Group type: EXPERIMENTAL
Intervention: Full version of MASI app
Number of subjects: 50

Group type: COMPARATOR
Intervention: Information-only version of the app
Number of subjects: 50
Study: 37725429

Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support health education program
Number of subjects: 60
Study: 37725490

Group type: EXPERIMENTAL
Intervention: CT-based muscle metrics analysis using machine learning algorithms and human quality assurance
Number of subjects: 3804

Group type: EXPERIMENTAL
Intervention: CT-based muscle metrics analysis
Number of subjects: 3804
Study: 37725576

Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Targetable genomic alterations affecting PDGFRA
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PDGFRA mutation p.D842N
Number of subjects: 15
Study: 37725613

Group type: EXPERIMENTAL
Intervention: High dose physical therapy intervention initiated in the NICU and continuing to 12 months of age, with twice-weekly sessions and caregiver-guided activities
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 192
Study: 37725680

Group type: EXPERIMENTAL
Intervention: Nesiritide treatment in decompensated heart failure
Number of subjects: 2680
Study: 37725919

Group type: EXPERIMENTAL
Intervention: Patiromer (8.4-33.6 g/day for 12 months)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control (Salford Kidney Study cohort)
Number of subjects: 304
Study: 37726068

Group type: EXPERIMENTAL
Intervention: Miracle fruit (MF) tablet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo-sugar candy
Number of subjects: 50
Study: 37726122

Group type: EXPERIMENTAL
Intervention: Invitation in language of origin and Norwegian
Number of subjects: 11347

Group type: COMPARATOR
Intervention: Norwegian only
Number of subjects: 11347
Study: 37726298

Group type: EXPERIMENTAL
Intervention: ixazomib-lenalidomide-dexamethasone (IRd) following three cycles of bortezomib-based induction
Number of subjects: 140
Study: 37726457

Group type: EXPERIMENTAL
Intervention: 80-kVp and 70-kVp tube voltage with adapted tube current
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard 120-kVp protocol
Number of subjects: 170